



HOTUNG INVESTMENT HOLDINGS LIMITED

(Incorporated in Bermuda)

LISTING OF AN INVESTEE COMPANY – FORESEE PHARMACEUTICALS CO., LTD.

1. INTRODUCTION

The Board of Directors of Hotung Investment Holdings Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) wishes to announce the listing of one of its investee companies, Foresee Pharmaceuticals Co., Ltd. (“**Foresee**”), on the Taipei Exchange on 29 June 2018.

The Group had invested in Foresee since February 2016.

2. INFORMATION ON FORESEE

Foresee is a clinical-stage pharmaceutical company. The core competency of Foresee includes rapid development and commercialization of new drugs using its proprietary drug delivery technology, the Stabilized Injectable Formulation platform (SIF), as well as developing first-in-class New Chemical Entity (NCE) in disease areas of high unmet medical needs.

Based on its core competency, Foresee has developed two global patent protected new drugs, FP-001 and FP-025, currently in clinical development stage. The FP-001 50mg phase 3 registration study in advanced prostate cancer has successfully hit the primary endpoints and another formulation of 25mg is currently on the phase 3 registration trial. The FP-025, a small molecule MMP-12 inhibitor for the treatment of asthma / chronic obstructive pulmonary disease, just launched its phase 2 study in Netherlands.

In 2017, Foresee and Switzerland based pharmaceutical company, Ferring Pharmaceuticals (“**Ferring**”), have entered into an exclusive worldwide development and option agreement to leverage Foresee’s proprietary and unique Stabilized Injectable Formulation platform (SIF) for the development of long duration, controlled release formulations of a peptide therapeutic. Under the terms of the agreement, Ferring will fund the development work and, upon completion, Ferring will have the right to exercise its option and enter into a definitive agreement with Foresee.

Foresee's management team consists of seasoned pharmaceutical professionals with many years of industry experience in pharmaceutical R&D and management. To rapidly advance its pipeline products, Foresee has also teamed up with a network of advisors and consultants in the area of medical, legal, regulatory, business development, and commercial, among others. Foresee has also established long-term partnerships with commercial contract manufacturers (CMOs) of drug substance and drug product, and other supply chain vendors to manage clinical trial materials and future commercial supplies. These partnerships provide the resources and flexibility required to rapidly advance an asset from research to development and eventually to commercialization.

Shareholders and other investors are reminded to exercise caution when dealing in the shares of the Company. In the event that the Shareholders and other investors are in doubt about the actions they should take, they should consult their stockbrokers, bank managers, solicitors, accountants or other professional advisers.

BY ORDER OF THE BOARD

Hsin-Chieh Chung
Company Secretary
29 June 2018